Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multipl...
| 发表在: | Кардиоваскулярная терапия и профилактика |
|---|---|
| Main Authors: | , |
| 格式: | 文件 |
| 语言: | 俄语 |
| 出版: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| 主题: | |
| 在线阅读: | https://cardiovascular.elpub.ru/jour/article/view/1799 |
| 总结: | Beta-adrenoblockers, included in any cardiovascular disease treatment standard, became a key part of clinical practice only in late XX century. Nebivolol is a highly selective beta-1 -adrenoiblocker, modulating endothelial NO release and subsequent physiological vasodilatation. Nebivolol has multiple clinical indications, including coronary heart disease, arterial hypertension, and chronic heart failure. Due to its super-selectivity it can also be beneficial in patients with diabetes mellitus, chronic obstructive pulmonary disease, and erectile dysfunction. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |